Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2PK5

Crystal Structure of HIV-1 Protease (Q7K, L33I, L63I ) in Complex with KNI-10075

Summary for 2PK5
Entry DOI10.2210/pdb2pk5/pdb
Related PRD IDPRD_000576
DescriptorProtease, (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-({N-[(isoquinolin-5-yloxy)acetyl]-3-(methyl sulfonyl)-L-alanyl}amino)-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, GLYCEROL, ... (4 entities in total)
Functional Keywordsprotease complex, viral protein, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHuman immunodeficiency virus 1
Cellular locationGag-Pol polyprotein: Host cell membrane ; Lipid-anchor. Matrix protein p17: Virion membrane; Lipid- anchor . Capsid protein p24: Virion . Nucleocapsid protein p7: Virion . Reverse transcriptase/ribonuclease H: Virion . Integrase: Virion : P03367
Total number of polymer chains2
Total formula weight22505.65
Authors
Armstrong, A.A.,Lafont, V.,Kiso, Y.,Freire, E.,Amzel, L.M. (deposition date: 2007-04-17, release date: 2007-05-08, Last modification date: 2023-08-30)
Primary citationLafont, V.,Armstrong, A.A.,Ohtaka, H.,Kiso, Y.,Mario Amzel, L.,Freire, E.
Compensating enthalpic and entropic changes hinder binding affinity optimization.
Chem.Biol.Drug Des., 69:413-422, 2007
Cited by
PubMed Abstract: A common strategy to improve the potency of drug candidates is to introduce chemical functionalities, like hydrogen bond donors or acceptors, at positions where they are able to establish strong interactions with the target. However, it is often observed that the added functionalities do not necessarily improve potency even if they form strong hydrogen bonds. Here, we explore the thermodynamic and structural basis for those observations. KNI-10033 is a potent experimental HIV-1 protease inhibitor with picomolar affinity against the wild-type enzyme (K(d) = 13 pm). The potency of the inhibitor is the result of favorable enthalpic (DeltaH = -8.2 kcal/mol) and entropic (-TDeltaS = -6.7 kcal/mol) interactions. The replacement of the thioether group in KNI-10033 by a sulfonyl group (KNI-10075) results in a strong hydrogen bond with the amide of Asp 30B of the HIV-1 protease. This additional hydrogen bond improves the binding enthalpy by 3.9 kcal/mol; however, the enthalpy gain is completely compensated by an entropy loss, resulting in no affinity change. Crystallographic and thermodynamic analysis of the inhibitor/protease complexes indicates that the entropy losses are due to a combination of conformational and solvation effects. These results provide a set of practical guidelines aimed at overcoming enthalpy/entropy compensation and improve binding potency.
PubMed: 17581235
DOI: 10.1111/j.1747-0285.2007.00519.x
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

236060

PDB entries from 2025-05-14

PDB statisticsPDBj update infoContact PDBjnumon